Generally, sarcopenia has emerged as a promising imaging-derived biomarker reflecting host physiology, immune competence and systemic inflammation.28 Unlike molecular biomarkers such as PD-L1 expression and tumor mutation burden, which have shown limited predictive utility in immunotherapy, muscle status provides a comprehensive, patient-level insight into biological reserve and treatment tolerance. This evidence concerns the gene CD274 and sarcopenia.